False-Negative Result for Cocaine Metabolites on a Lateral-Flow Drug Test Slide Corrected by Dilution

To the Editor:
Cocaine is one of the most widespread drugs of abuse; therefore, clinical laboratories are frequently requested to screen for the presence of cocaine and its metabolites in urine. When screening a urine specimen from a potential study participant for drugs of abuse, using a Verdict TM II lateral flow test slide (MEDTOX TM Diagnostics), multiple technologists obtained a negative screening result for benzoylecgonine (BE) on repeat analysis (n ϭ 25). Because the study participant did not show symptoms of cocaine toxicity despite admitting to cocaine use and because the Verdict II drug test slide gave a negative result, the urine specimen was sent to Mayo Medical Laboratory (Rochester, MN) for a comprehensive drug screen and confirmation of cocaine and its metabolites by gas chromatography-mass spectrometry (Model 5973; Agilent TM Technologies) using solid-phase extraction and trimethylsilyl derivatization, as described by Chinn et al.
(1 ). Gas chromatographic-mass spectrometric testing indicated that the urine specimen contained high concentrations of BE (Table 1) . A negative cocaine screen result on the urine specimen was also observed with the OnTrak TesTcup TM Pro 5 (lot 7131001S; Varian Diagnostic Products; n ϭ 3). The internal controls (MEDTOX Diagnostics) and a positive benzodiazepine result for the urine specimen indicated proper function of the Verdict II slide and OnTrak TesTcup Pro 5 for the specimen in question. The specific gravity, osmolality, dipstick, microscopic examination, and appearance were consistent with a normal urine sample, albeit dilute ( Table 1) .
Analysis of the urine specimen by MEDTOX Diagnostics detected no adulterants [nitrites, chromium, glutaraldehyde, or oxidants (i.e., bleach)]. In addition, the Verdict II slide (lot 23), when tested by the manufacturer with urine samples containing 16 000 -157 000 g/L BE, gave a positive cocaine screen result, indicating absence of a high-dose hook effect.
The negative screening result for the urine specimen containing BE at nearly 50-fold above the test cutoff of 300 g/L led to further investigation. Notably, we found that the drug test slide gave positive results for cocaine when the urine was diluted 1:1 or greater with distilled water (n ϭ 5; Table 1 ) or on lesser dilution with 1 mol/L sodium chloride (data not shown).
When the urine specimen was ultrafiltered through Centricon YM-3 membranes (M r 3000 cutoff; Amicon), the ultrafiltrate tested negative for cocaine on the drug test slide and again became positive on dilution (n ϭ 5; Table 1 ). This ruled out interference from large molecules such as proteins or from binding of BE to large aggregates that would be removed by ultrafiltration.
Testing of the urine sample with two other lots of Verdict II slides (lots 25 and 28) yielded consistently positive results for cocaine as well as for benzodiazepines and opiates, but negative results for amphetamines and cannabinoids with both lots (n ϭ 10). It therefore appears that the observed interference in cocaine screening was lot dependent. As part of the screening protocol for the drug study, a second urine specimen was submitted 10 days later from the same person and was positive for cocaine, benzodiazepines, and opiates with lots 23, 25, and 28 of the Verdict II drug test slide (n ϭ 5); therefore, no interference was apparent at that time.
Many adulterants for urine have been described that can lead to falsenegative results, but generally, interference is not corrected by dilution (2 ) . We hypothesize that compounds in an herbal supplement (not specified) that this individual admitted taking during the first but not the second urine specimen bind weakly with BE and that this complex dissociates on specimen dilution with water or saline solution. This may be similar to the reported masking effects of benzalkonium chloride (Visine TM ) with the enzyme-multiplied immunoassay technique and TDx TM (Abbott Laboratories) assays for 9-carboxy-tetrahydrocannabinol; the drug is proposed to partition into micelles formed by benzalkonium chloride so that it is not accessible to antibodies (3 ). The matrix components of different slide lots may vary in our experiments and affect dissociation of the complex between BE and binding components in urine. Intermolecular association may provide a mechanism for interference with selected components in lateral flow assay, accounting for interference with BE but not benzodiazepine and opiate detection. Because the two urine specimens from the above individual tested positive for cocaine, opiates, and benzodiazepine, that person was excluded from the drug study. To the Editor: Mutations in the glucokinase gene lead to an impaired sensing of blood glucose by the pancreatic ␤ cell, causing an autosomal dominant form of type 2 diabetes, maturity-onset diabetes of the young type 2 (MODY2). Usually, MODY2 patients present with high fasting blood glucose (6 -12 mmol/L) from an early age (1 ). This situation should significantly increase their risk for diabetic complications (2 ), but whereas other forms of diabetes typically lead to macrovascular complications, MODY2 patients rarely develop diabetes-related problems (3 ) .
In a family with autosomal dominant diabetes, we identified a novel C3 A substitution in the glucokinase gene at nucleotide position 695 [A232D (pancreatic isoform), A231D (liver isoform)] in all affected individuals (Fig. 1) . Codon 232 is highly conserved among nine different species. The mutation was not detected in 192 control chromosomes. Studied mutations around codon 232 (T228M and G261R) cause the lowest glucokinase activities of all mutations tested to date and suggest similar effects of A232D (4 ).
On the basis of our findings, we determined that individuals 0307 and 0309 were probably misdiagnosed with type 1 diabetes and individuals 0301 and 0304 with gestational diabetes. However, individual 0305 was an unaffected mutation carrier, which is not uncommon for MODY.
High Fig.  1B) , we made the same observation (6 ). In both families, the difference for triglycerides was significant (P ϭ 0.025, two-sided test; 7 unaffected and 13 affected individuals), but we had no homozygous mutation carrier and too few cases to make a general statement.
It is possible that glucokinase mutations lead to lower triglycerides, even within their reference interval (0.35-2.30 mmol/L). Glucokinase mutations impair glycolysis, which is responsible for delivering glyceraldehyde 3-phosphate as the later glycerol backbone of triglycerides (4 ). Transgenic mice overexpressing glucokinase develop hypertriglyceridemia in addition to other effects, indicating a direct link between glucokinase activity and triglyceride regulation (7 ). There is evidence that serum concentrations of triglycerides are directly correlated with rates of progression of coronary artery disease and other macrovascular complications (8 -10 ). In the studied family, and in concordance with the much lower frequency of diabetic complications in known MODY2 families, only one individual (0205) had a macrovascular event (myocardial infarction).
In conclusion, impaired glucokinase activity could lead to particularly low triglycerides in the circulation. The contribution of triglycerides Clinical Chemistry 51, No. 4, 2005 
